Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT01221168 Recruiting - Prostate Cancer Clinical Trials

Epidemiologic and Genetic Study on Familial Prostate Cancer

Start date: October 1996
Phase: N/A
Study type: Observational

The aims of the study are: - to identify genetic and molecular factors (rare mutations, polymorphisms) involved in the natural history of prostate cancers and their response to treatment, - to evaluate and deduce their medical applications for screening and therapeutic management of these tumors.

NCT ID: NCT01209988 Recruiting - Clinical trials for Prostatic Neoplasms, Prostatectomy

Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy

Start date: April 2010
Phase: N/A
Study type: Interventional

To date, there is a lack of consensus concerning the optimal timing for removal of the urethral catheter, its related complications, the effectiveness in prophylactic drug use to reduce complication, and the patient reported outcomes (quality of life) after robot-assisted laparoscopic prostatectomy (RALP). The purpose of this study is to determine the impact of tamsulosin on voiding patterns following early urethral catheter removal after RALP for prostate cancer.

NCT ID: NCT01194648 Recruiting - Prostate Cancer Clinical Trials

Focal Therapy for Prostate Cancer Using HIFU

INDEX
Start date: June 29, 2011
Phase: N/A
Study type: Interventional

RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men achieving trifecta status (no erectile dysfunction, leak-free pad-free continence, cancer control). However, these trials have involved small numbers of patients with men selected for good baseline function. A multi-centre prospective trial within a larger cohort of men that better represents the patient population with prostate cancer (external validity) is required.

NCT ID: NCT01193855 Recruiting - Prostate Cancer Clinical Trials

Dutasteride in Treating Patients With Prostate Cancer

Start date: June 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well giving dutasteride works in treating patients with prostate cancer.

NCT ID: NCT01191099 Recruiting - Prostate Cancer Clinical Trials

Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance

Start date: August 2010
Phase: Phase 3
Study type: Observational

A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer

NCT ID: NCT01177865 Recruiting - Prostate Cancer Clinical Trials

Study of Treatment Choice in Patients With Localized Prostate Cancer

Start date: September 2010
Phase: N/A
Study type: Interventional

RATIONALE: Gathering information about patients with prostate cancer may help doctors learn more about how patients choose treatment options. PURPOSE: This study is looking at treatment choice in patients with localized prostate cancer.

NCT ID: NCT01089881 Recruiting - Prostate Cancer Clinical Trials

The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer

Start date: January 2008
Phase: N/A
Study type: Observational

Choline is one of the components of phosphatidylcholine, an essential element of phospholipids in the cell membrane. Some malignant cells show their ability to actively incorporate choline to produce phosphocholine and phosphatidylcholine to facilitate tumor cell duplication. The efficacy of 18F-fluorocholine (18F-FCH) for localizing primary or metastatic prostate cancer has been recently reported in limited studies. This study will be conducted to delineate the effectiveness of 18F-FCH PET in (1) differentiating benign prostate hypertrophy (BPH) from prostate cancer, (2) staging prostate cancer, (3) following-up patients with prostate cancer after initial curative therapy.

NCT ID: NCT01087268 Recruiting - Prostate Cancer Clinical Trials

Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer

Start date: January 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer. It is not yet known whether high-pressure oxygen is effective in treating adverse effects caused by radiation therapy. PURPOSE: This randomized phase III trial is studying hyperbaric oxygen therapy to see how well it works in treating long-term gastrointestinal adverse effects caused by radiation therapy in patients with pelvic cancer.

NCT ID: NCT01048151 Recruiting - Clinical trials for Locally Advanced Prostate Cancer

TNFerade Biologic to Treat Locally Advanced Prostate Cancer

Start date: n/a
Phase: Phase 1
Study type: Interventional

While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer. New treatments are being combined with radiation therapy in an effort to further improve the cure rates. This study proposes to combine an experimental drug, TNFeradeā„¢ Biologic, (also called AdGVEGR.TNF.11D or "TNFerade") at different dose (amounts) levels in combination with radiation. TNFeradeā„¢ Biologic is a form of gene transfer therapy that when injected into the tumor has shown to increase the effect of radiation therapy.

NCT ID: NCT01045148 Recruiting - Prostate Cancer Clinical Trials

CyberKnife Radiosurgery for Localized Prostatic Carcinoma

Start date: March 2006
Phase: Phase 2
Study type: Interventional

Virtual high dose rate (HDR) CyberKnife (CK) prostate treatment has comparable morbidity and efficacy compared with actual prostate HDR treatment, but does it without the catheters and hospital admission. As such, it is a more "patient friendly" treatment method compared with actual prostate HDR brachytherapy as currently practiced. Related, as has previously been reported with actual prostate HDR treatment, Virtual HDR CyberKnife prostate treatment should have a high efficacy but with lower acute and chronic morbidity compared with other local prostate cancer treatment methods such as permanent seed prostate brachytherapy.